Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focusing on creating value for people living with neurology and immunology conditions.
Celebrating 90 years of innovation #UCB90
Twitter Feed
-
Great to see some of our exciting new research published! https://t.co/OiyO2iil6Z
— UCB News (@ucb_news) 16.10.2018 -
#Psoriasis is one of the most common chronic inflammatory diseases, and often carries significant emotional and social burdens. Learn more here: https://t.co/6hstn11Fra #AIMotherhood https://t.co/b6O7O3C0pF
— UCB News (@ucb_news) 15.10.2018 -
#DYK there are 7 million people in the US with #psoriasis, and women of childbearing age often face unique challenges? Whats your psoriasis story? https://t.co/aF5471jQDN #AIMotherhood https://t.co/1m7V9fiRDE
— UCB News (@ucb_news) 15.10.2018
Highlights
UCB Ventures, a strategic corporate venture fund established in 2017 to further strengthen UCB’s ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases, has announced its first direct investment.
